A new study published in the journal Science Translational Medicine describes a genetic change common to 80 percent of human melanomas, the most deadly form of skin cancer, and also describes a molecule that seeks out cells marked by this genetic change. The current study attaches a radioactive label to the targeting molecule and uses positron emission tomography (PET) imaging to show that the radiolabeled molecule does, in fact, seek out and bind to melanoma cells. Using a similar approach, it may be possible to not only image these cells, but to attach therapy to this targeting molecule to kill these melanoma cells.
The work starts with a protein called melanocortin-1 receptor (MC1R), which is involved in determining skin and hair color, but which is also found at a higher level on the surface of more than 80 percent of human melanomas. The current study describes a "peptide" that specifically binds to MC1R. If MC1R is a lock, then the peptide 68Ga-DOTA-GGNle-CycMSHhex is the key that fits it. In this case, researchers attached an imaging radionuclide to this peptide - the combination of peptide and radionuclide found, bound, and "lit up" melanoma metastases, allowing researchers to image these melanoma cells.
The success of this molecular targeting approach suggests the possibility of using the peptide as a delivery vehicle to transport a therapeutic radionuclide directly to melanoma cells marked with MC1Rs for therapy.
"Basically, we attach the imaging radionuclide to the peptide, then the radiolabeled peptide finds MC1Rs on the melanoma through blood circulation, allowing us to use a PET machine to gather the signals from the radiolabeled peptide for melanoma imaging. It's a very sensitive way to see melanoma," says the senior author.
In addition, researchers were able to replace the radiolabel with a fluorescent one to generate a new MC1R-targeting fluorescence imaging probe (called Cy5.5-GGNle-CycMSHhex). The current study shows that the fluorescent probe binds and stains MC1Rs on melanoma cells and lesions. The author sees that the combination of these two approaches - one radiolabeled and one fluorescent - may potentially improve surgical outcomes for melanoma via imaging-guided surgery.
"Approximately 60 percent of patients with metastatic melanoma develop brain metastases during the course of their disease. Patients with brain metastases have much shorter life expectancies than patients without brain metastases. Our study shows that the MC1R continues to mark melanoma cells even after these cells metastasize from the site of origin to brain, and this peptide can bind to MC1Rs in melanoma brain metastases. One potential application for this technology is to use our imaging systems to identify MC1R-postive melanoma tumors and then treat these lesions with therapies delivered by this peptide," the senior author says.
For now, the current study demonstrates the first-in-human ability to image melanoma metastases using the group's radiolabeled peptide.
https://coloradocancerblogs.org/targeting-mc1r-in-metastatic-melanoma/
http://stm.sciencemag.org/content/10/466/eaau4445
Latest News
How the brain fine-tunes it…
By newseditor
Posted 25 Apr
Immune cells carry a long-l…
By newseditor
Posted 25 Apr
Mutations in noncoding DNA…
By newseditor
Posted 24 Apr
More influence of environme…
By newseditor
Posted 24 Apr
The assembly of the human c…
By newseditor
Posted 24 Apr
Other Top Stories
Prognostic biomarker found in ovarian cancer patients
Read more
Identical driver gene mutations found in metastatic cancers
Read more
How a sleeping cancer awakens and metastasizes
Read more
Cancer increases glucose supply by hijacking microbiome!
Read more
"Check Point Theory" to treat cancer wins 2018 Nobel Prize in Physi…
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
The MYCN 50 UTR as a therap…
By newseditor
Posted 25 Apr
Control of neuronal excitat…
By newseditor
Posted 25 Apr
Epithelial UNC-23 limits me…
By newseditor
Posted 25 Apr
Macrophage memories of earl…
By newseditor
Posted 25 Apr
A gut-derived hormone regul…
By newseditor
Posted 25 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar